New heartburn drug candidate tested for heart safety in healthy volunteers

NCT ID NCT05469854

Recruiting now Knowledge-focused Sponsor: Cinclus Pharma Holding AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 trial is testing a new drug called linaprazan glurate in 121 healthy adults to see how the body absorbs and processes it, and whether it affects heart rhythm. The study is double-blind and placebo-controlled, meaning some participants get a dummy pill. It is an early step to gather safety data before testing the drug in people with GERD (chronic acid reflux).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: linaprazan glurate
What this could lead to: If successful, this trial could help determine safe dosing and heart safety for a potential new GERD treatment.
What could go wrong: This is an early Phase 1 study in healthy people, not patients. It only tests safety and drug processing, not whether it works for GERD. Results may not predict effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIODYNAMIC ECG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIODYNAMIC ECG GERD PHARMACOKINETICS SAFETY, AND TOLERABILITY

Contacts and locations

Locations

CTC Clinical Trial Consultants AB
RECRUITING

Uppsala, SE-75237, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.